- Home
- HTO vs IMCR Comparison
HTO vs IMCR Comparison
Compare HTO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTO | IMCR |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | United States | United Kingdom |
| Employees | 837 | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.7B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HTO | IMCR |
|---|---|---|
| Price | $58.14 | $31.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $62.25 | ★ $64.70 |
| AVG Volume (30 Days) | ★ 462.6K | 405.1K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $10.26 | $14.57 |
| Revenue Next Year | $7.06 | $8.21 |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $43.75 | $26.37 |
| 52 Week High | $60.18 | $40.71 |
Technical Indicators
Market Signals| Indicator | HTO | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 53.58 | 53.69 |
| Support Level | $55.29 | $31.08 |
| Resistance Level | $59.00 | $34.35 |
| Average True Range (ATR) | 1.34 | 1.17 |
| MACD | -0.10 | 0.22 |
| Stochastic Oscillator | 56.68 | 71.76 |
Price Performance
Historical ComparisonAbout HTO H2O America
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.